527.1

-0.21%↓

SANES

10.534

-0.62%↓

BBVA

20.1

-0.35%↓

BNP

93.81

+1.37%↑

CABK

10.72

+0.37%↑

527.1

-0.21%↓

SANES

10.534

-0.62%↓

BBVA

20.1

-0.35%↓

BNP

93.81

+1.37%↑

CABK

10.72

+0.37%↑

527.1

-0.21%↓

SANES

10.534

-0.62%↓

BBVA

20.1

-0.35%↓

BNP

93.81

+1.37%↑

CABK

10.72

+0.37%↑

527.1

-0.21%↓

SANES

10.534

-0.62%↓

BBVA

20.1

-0.35%↓

BNP

93.81

+1.37%↑

CABK

10.72

+0.37%↑

527.1

-0.21%↓

SANES

10.534

-0.62%↓

BBVA

20.1

-0.35%↓

BNP

93.81

+1.37%↑

CABK

10.72

+0.37%↑

Начало・Списък с акции・Ipsen SA.

Ipsen SA.

Отворен

СекторФинансови

148.1 7.32

Купи Продай

Преглед

Промяна на цената на акция

24 ч

Текуща

Минимум

137.2

Максимум

152.2

Ключови измерители
By Trading Economics
Приходи	334M
Продажби	1.8B
P/E Средно за сектора	25.632 26.803
Дивидентна доходност	1.03
Марж на печалбата	18.354
Служители	5,358
EBITDA	637M

Препоръки
By TipRanks
Препоръки	Неутрален
12-месечна прогноза	-7.66% downside

Дивиденти
By Dow Jones
Дивидентна доходност Средно за сектора	1.03% 4.24%
Следващи печалби	12.02.2026 г.

Пазарни показатели
By TradingEconomics
Пазарна капитализация	11B
Предишно отваряне	140.78
Предишно затваряне	148.1

Настроения в новините

By Acuity

40%

60%

118 / 444 Класиране в Finance

Техническа оценка

By Trading Central

Увереност

Strong Bullish Evidence

99.85 / 104 Подкрепа & съпротива

Ipsen SA. Графика

Миналото представяне не гарантира бъдещи резултати.

Свързани новини

11.02.2026 г., 23:47 ч. UTC

Горещи акции

Stocks to Watch: AppLovin, Cisco, Cognex, Pilgrim's Pride

11.02.2026 г., 22:59 ч. UTC

Печалби

Придобивния, сливания и поглъщания

Grab Holdings to Buy U.S.-Based Stash Financial

11.02.2026 г., 23:54 ч. UTC

Печалби

McDonald's Says Its Value Campaign Is Paying Off -- 2nd Update

11.02.2026 г., 23:50 ч. UTC

Пазарно говорене

Global Equities Roundup: Market Talk

11.02.2026 г., 23:50 ч. UTC

Пазарно говорене

Nikkei May Rise on Hopes for Takaichi's Economic Steps -- Market Talk

11.02.2026 г., 23:49 ч. UTC

Печалби

Singtel: Key Focus Areas Are Strengthening Core Businesses, Scaling Growth Engines, Building Momentum Across Regional Associates >Z74.SG

11.02.2026 г., 23:45 ч. UTC

Печалби

Singtel: Net Exceptional Gain of S$1.15B in 3Q Primarily From Sale of Partial Stake in Bharti Airtel>Z74.SG

11.02.2026 г., 23:42 ч. UTC

Печалби

Singtel 3Q Underlying Net Profit S$744M Vs. S$680M >Z74.SG

11.02.2026 г., 23:41 ч. UTC

Печалби

Singtel 3Q Net S$1.89B Vs. Net S$1.32B >Z74.SG

11.02.2026 г., 23:40 ч. UTC

Печалби

Singtel 3Q Operating Revenue S$3.66B Vs. S$3.63B >Z74.SG

11.02.2026 г., 23:35 ч. UTC

Пазарно говорене

Gold Falls on Prospects of Long Fed Pause -- Market Talk

11.02.2026 г., 23:18 ч. UTC

Пазарно говорене

AppLovin CEO Looks to Soothe Concerns Over AI, Competition -- Market Talk

11.02.2026 г., 23:14 ч. UTC

Пазарно говорене

RBA Governor Faces Barrage of Questions About Govt Spending -- Market Talk

11.02.2026 г., 22:59 ч. UTC

Печалби

Kakao 2025 Net KRW525.72B Vs. Loss KRW161.87B >035720.SE

11.02.2026 г., 22:59 ч. UTC

Печалби

Kakao 2025 Oper Pft KRW732.04B Vs. Pft KRW460.21B >035720.SE

11.02.2026 г., 22:59 ч. UTC

Печалби

Kakao 2025 Rev KRW8.099T Vs. KRW7.872T >035720.SE

11.02.2026 г., 22:58 ч. UTC

Печалби

Kakao 4Q Net Loss Missed FactSet-Compiled Consensus

11.02.2026 г., 22:57 ч. UTC

Печалби

Kakao 4Q Loss KRW39.30B Vs. Loss KRW395.21B >035720.SE

11.02.2026 г., 22:54 ч. UTC

Печалби

Kakao 4Q Oper Pft KRW203.45B Vs. Pft KRW75.43B >035720.SE

11.02.2026 г., 22:53 ч. UTC

Печалби

Kakao 4Q Rev KRW2.133T Vs. KRW1.957T >035720.SE

11.02.2026 г., 22:47 ч. UTC

Печалби

AppLovin Reports Strong Earnings. The Stock Is Down. -- Barrons.com

11.02.2026 г., 22:47 ч. UTC

Печалби

AppLovin Reports Strong Earnings. The Stock Is Down. -- Barrons.com

11.02.2026 г., 22:23 ч. UTC

Печалби

Grab Holdings Expects to Close Stash Acquisition in 3Q of 2026 >GRAB

11.02.2026 г., 22:22 ч. UTC

Печалби

Grab Holdings to Acquire U.S. Digital Financial Services Company Stash Financial >GRAB

11.02.2026 г., 22:22 ч. UTC

Печалби

Grab Holdings Sees FY26 Adj Ebitda $700M to $720M >GRAB

11.02.2026 г., 22:19 ч. UTC

Печалби

Grab Holdings Sees FY26 Rev $4.04B to $4.10B >GRAB

11.02.2026 г., 22:18 ч. UTC

Печалби

Grab Holdings 4Q Adj Ebitda $148.0M Vs. $97.0M >GRAB

11.02.2026 г., 22:18 ч. UTC

Печалби

Grab Holdings 4Q Net $153.0M Vs. Net $11.0M >GRAB

11.02.2026 г., 22:18 ч. UTC

Печалби

Grab Holdings 4Q Oper Pft $52.0M Vs. $2.0M >GRAB

11.02.2026 г., 22:16 ч. UTC

Печалби

Grab Holdings 4Q Rev $906.0M Vs. $764.0M >GRAB

Сравнение с други в отрасъла

Ценова промяна

Ipsen SA. Прогноза

Ценова цел

By TipRanks

-7.66% надолу

12-месечна прогноза

Среден 129 EUR -7.66%

Висок 137 EUR

Нисък 120 EUR

Според 3 анализатори от Wall Street, предложили 12-месечна ценова цел за Ipsen SA. през последните три месеца.

Консенсусна оценка

By TipRanks

Неутрален

3 ratings

Купи

Задържане

Продай

Според 3 анализатори, дали борсови рейтинги на Ipsen SA. през последните 3 месеца.

Техническа оценка

By Trading Central

99.85 / 104Подкрепа & съпротива

Bullish events outweigh bearish events.

Recent bearish events outweigh bullish events.

Bearish events outweigh bullish events.

Настроение

By Acuity

118 / 444 Класиране в Финансови

Финанси

Продажбени и админисративни разходи

Оперативни разходи

Печалба преди облагане с данъци

Продажби

Разходи за продажби

Брутна печалба от продажби

Разходи за лихви по дълг

EBITDA

Оперативна печалба

Относно Ipsen SA.

Ipsen S.A. operates as a biopharmaceutical company worldwide. The company provides drugs in the areas of oncology, neuroscience, and rare diseases. Its product pipeline comprises Cabometyx + Atezolizumab, which is in phase III clinical trial for the treatment of second line metastatic castration-resistant prostate cancer; lenalidomide and rituximab, and Taverik, which is in phase III for the treatment of second line follicular lymphoma; Bylvay, which is in phase III for the treatment of biliary atresia; Dysport, which is in phase III clinical trial for the treatment of chronic and episodic migraine; Fidrisertib, which is in phase II clinical trial for the treatment of fibrodysplasia ossificans progressiva; Elafibranor, which is in phase II for the treatment of primary sclerosing cholangitis, as well as IPN60250; IPN10200, which is in phase II for the treatment of longer-acting neurotoxin aesthetics and therapeutics; IPN60210, which is in phase I clinical trial for the treatment of relapsed/refractory multiple myeloma; and IPN60260 for the treatment of Viral cholestatic disease and is in phase I clinical trial. The company also offers Somatuline, Decapeptyl, Cabometyx, Onivyde, Tazverik, and other oncology products; Dysport and other neurosciences products; and Bylvay, NutropinAq, Increlex, and Sohonos for rare diseases. The company was founded in 1929 and is based in Boulogne-Billancourt, France.